Article Text

Download PDFPDF
Pharmacogenetic-guided and standard dosing did not differ for out-of-range INRs in patients initiating warfarin therapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

J L Anderson

Dr J L Anderson, Intermountain Medical Center, Murray, UT, USA;



randomised controlled trial (RCT).


unclear allocation concealment.*


blinded (clinicians and patients).*



anticoagulation clinic at Intermountain Healthcare, Utah, United States.


206 patients 18–86 years of age (mean age 61 y, 53% men, based on 200 patients) in whom anticoagulation with a target international normalised ratio (INR) range of 2–3 was indicated. Exclusion criteria included pregnancy, lactation, and comorbidities precluding standard dosing (eg, advanced physiological age, serum creatinine level >2.5 mg/dl, hepatic insufficiency, and terminal disease).


warfarin initiation with pharmacogenetic-guided dosing (PGD, n = 101) or standard dosing (SD, n = 99). PGD was based on a regression equation that included genotype, age, sex, and weight and generated scores in 14 dose increments from 1–8 mg/day; twice the dose was given on the first 2 days, and subsequent dose modification was based on INR. SD was …

View Full Text


  • Source of funding: Deseret Foundation; Heart and Lung Institute; LDS Hospital; Intermountain Healthcare; Critical-Path Institute.